undamentalytics Newsletter
Sign in

Embecta Corp. key statistics and ratios

In fiscal 2025, Embecta Corp. had an operating margin of 22.4% and a current ratio of 2.41. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Sept 20202021Sept 20212022Sept 20222023Sept 20232024Sept 20242025Sept 2025LTMJun 2026
Gross margin70.3%68.7%68.6%66.9%65.5%62.6%59.0%
Operating margin44.8%42.2%27.4%19.8%14.9%22.4%21.9%
Net margin39.4%35.6%19.8%6.3%7.0%8.8%8.6%
Free-cash-flow margin42.1%36.0%34.4%3.7%1.8%16.9%16.2%
Return on equity74.7%71.1%—————
Return on assets—52.6%23.9%6.1%6.3%8.0%7.4%
Asset turnover—1.481.210.970.900.910.86
Current ratio—1.782.212.122.032.411.68
Debt to equity0.0%0.0%—————
Effective tax rate12.0%16.2%12.9%33.4%—30.0%30.0%
R&D as % of revenue5.7%5.4%5.9%7.6%7.0%3.5%2.0%
SG&A as % of revenue19.8%20.6%26.1%30.5%32.5%30.7%31.3%
Capital spending as % of revenue3.9%3.2%2.1%2.4%1.4%0.9%0.9%
Free cash flow ÷ net income106.8%101.1%173.8%58.5%25.4%191.2%188.1%
Dividends ÷ net income0.0%0.0%3.8%48.9%44.1%36.7%31.1%
Dividends and buybacks ÷ free cash flow0.0%0.0%2.2%83.5%173.4%19.2%16.5%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

1 of 3 checks passed · June 30, 2026
What it owns · $1.3bn
Short-term assets $705mLonger-term assets $560m
What it owes, and who funded it · $420m
Short-term liabilities $420mShareholders' equity $-613m
  • Short-term assets cover short-term liabilities $705m of assets due within a year against $420m of liabilities due within a year.
  • Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
  • More cash than debt $215m of cash against $1.5bn of debt.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt $174m of operating cash flow against $1.5bn of debt.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Embecta Corp.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

70 /100

Moderate moat

How hard Embecta's competitive advantage looks for rivals to wear away, judged from 5 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 10 / 20

    Net income has been a median 6.9% of total assets over 5 years.

  • Pricing power 18 / 20

    Gross margin has been a median 66.4%, moving by 3.8 percentage points (standard deviation) across 5 years.

  • Durability 16 / 20

    Operating margin has been a median 19.2%; its worst year was 14.9%.

  • Cash conversion 16 / 20

    Free cash flow was positive in 5 of 5 years, at a median 12.0% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (75 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: EMBC vs UFPTEMBC vs ICUIEMBC vs ORGO

More: Health Care Supplies stocks compared, Health Care sector, rankings of US companies

Figures from Embecta Corp.'s SEC filings (10-K and 10-Q), retrieved October 26, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Embecta Corp.